Autophagy and Neurodegeneration Webinar


11 21(12:00 AM) Autophagy field David C Rubinsztein Autophagy neuroprotective effects Webinar մϴ.  Bitotechne Webinar ûϼ. Webinar ߿ Ǹ Ͻ , Ͻø ġ Webinar ޹ ֽϴ.




Learning Objectives:


  • Autophagy basic biology ؿ neurodegeneration
  • Parkinsons disease, Alzheimers disease ׸ polyglutamine diseases Autophagosome  ġ




Intracellular protein aggregation is a feature of many lateonset neurodegenerative dis-eases, including Parkinsons disease, tauopathies, and polyglutamine expansion dis-eases such as Huntingtons disease. Therefore, the factors regulating their clearance are crucial for understanding disease pathogenesis and for developing rational therapeutic strategies. One of the major intracellular protein degradation pathways is (macro)auto-phagy. Dr. Rubinszteins team has extended the range of intracellular proteinopathy substrates that are cleared by autophagy to neurodegenerative diseases including Parkinsons disease.




About the Speaker:


David C Rubinsztein, M.B. Ch.B; B.Sc. (Med) Hons; Ph.D., FRCPath, FMedSci, FRS, is a UK Dementia Research Institute Professor, Professor of Molecular Neurogenetics at the University of Cambridge, Deputy Director of the Cambridge Institute for Medical Research and Academic Lead of the Alzheimers Research Cambridge Drug Discovery Institute. He has been a leader in the field of autophagy, particularly in the context of neurodegenerative diseases. His laboratory pioneered the strategy of autophagy upregulation as a possible therapeutic approach in various neurodegenerative diseases and has identified drugs and novel pathways that may be exploited for this objective. He has made key contributions to illuminating the relevance of autophagy defects as a disease mechanism and to the basic cell biology of this important catabolic process. His laboratory has also identified druggable pathways independent of autophagy that may be relevant to diseases caused by aggregate-prone proteins. These insights into a fundamental catabolic process open novel avenues for developing potential therapies. Dr. Rubinsztein has been elected as a Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, and as an EMBO member. He was awarded the Graham Bull Prize for Clinical Science (Royal College of Physicians), the Thudichum Medal (Biochemical Society) and the Roger the Spoelberch Prize for his contributions.


Helpful Links

Connect with Us

















ǰ : м ȱ ( / 02-881-5432 741)

Ʈ :()޵ / ȣ:()޵
ȭ: 02-881-5432 / FAX: 02-881-5454
Ư ı Ĵ201 ׶ŸA 1113ȣ (642)
CopyrightAll Rights Reserved Any questions to

-2018 11 15-